Genetic Markers in Triple-Negative Breast Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F18%3A73590695" target="_blank" >RIV/61989592:15110/18:73590695 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.clbc.2018.07.023" target="_blank" >http://dx.doi.org/10.1016/j.clbc.2018.07.023</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.clbc.2018.07.023" target="_blank" >10.1016/j.clbc.2018.07.023</a>
Alternative languages
Result language
angličtina
Original language name
Genetic Markers in Triple-Negative Breast Cancer
Original language description
riple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and is characterized by the absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Though TNBC is a highly heterogenic and aggressive disease, TNBC patients have better response to neoadjuvant therapy compared to other breast cancer subtypes. Nevertheless, patients with residual disease have a very poor prognosis, with higher probability of relapse and lower overall survival in the first years after diagnosis. TNBC has 6 subtypes with distinct molecular signatures with different prognoses and probably different responses to therapy. The precise stratification of TNBC is therefore crucial for the development of potent standardized and targeted therapies. In spite of intensive research into finding new molecular biomarkers and designing personalized therapeutic approaches, BRCA mutational status is the only clinically validated biomarker for personalized therapy in TNBC. Recent studies have reported several promising biomarkers that are currently being validated through clinical trials. The objective of this review was to summarize the clinically relevant genetic markers for TNBC that could serve as diagnostic, prognostic, or predictive or could improve personalized therapeutic strategies. (C) 2018 The Authors. Published by Elsevier Inc.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/LO1304" target="_blank" >LO1304: Support of suistainability of the Institute of Molecular and Translational Medicine</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Clinical Breast Cancer
ISSN
1526-8209
e-ISSN
—
Volume of the periodical
18
Issue of the periodical within the volume
5
Country of publishing house
US - UNITED STATES
Number of pages
10
Pages from-to
"E841"-"E850"
UT code for WoS article
000445702400017
EID of the result in the Scopus database
2-s2.0-85052062858